Study: NCT04184869

Intervention type: DRUG
Group type: OTHER
Intervention: Belinostat
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.

Intervention type: DRUG
Group type: OTHER
Intervention: Belinostat
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.

Intervention type: DRUG
Group type: OTHER
Intervention: Belinostat
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.

Intervention type: DRUG
Group type: OTHER
Intervention: Belinostat
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Belinostat Dose Cohort A \& B: 1000mg/m2 Belinostat Dose Cohort C: 750mg/m2 Frequency: once cycle of 21 days: cycle 1, Day 1 and Cycle1, Day 2 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.

Intervention type: DRUG
Group type: OTHER
Intervention: Atazanavir
Description: Patients can continue to receive belinostat treatment as described in the original study protocol or can be treated per the Investigator's standard of care.~Dose: 750mg/ m2 (Belinostat IV), 400mg (Atazanavir) Frequency: two cycles of 21 days (Belinostat administered through Cycle 2, Day 5) Atazanavir 400mg administered Cycle 1 Day 15 to Day 21, and Cycle 2 Day 1 to Day 5~Dose modifications to belinostat during treatment on this extension protocol will be in accordance with the belinostat package insert.~All patients who receive at least one dose of belinostat treatment in this extension study will be followed for safety through 35 (+/-5) days after their last dose of the treatment or until all treatment related AEs have resolved or returned to Baseline/Grade I, whichever is longer, or until it is determined by the treating physician that the outcome will not change with further follow-up.